Here, we report that this patient relapsed with a glioblastoma displaying compound loss of function mutations in NF1, suggesting that the dacomitinib was acting on target, inhibiting EGFR and selecting for EGFR-negative subclones. This evidence concerns the gene EGFR and glioblastoma.